Patients with the AG genotype and receiving warfarin following cardiac valve replacement may have an increased risk of bleeding at therapeutic INR as compared to patients with the AA genotype. Other genetic and clinical factors may also affect a patient's risk of bleeding while receiving warfarin therapy.